
6-Month RCT Secondary Analysis Shows 45-Minute Aerobic Sessions Four Times Weekly Improve Executive Function Scores in Postmenopausal Women
Secondary analysis of a 6-month RCT found that 180 minutes weekly of moderate aerobic exercise improved executive function in postmenopausal women within three months. Benefits appear mediated partly by gains in cardiorespiratory fitness. Larger primary-endpoint trials with imaging are required to establish durability and disease relevance.
The parent trial randomized 93 cognitively healthy women aged 20–67 with below-average fitness to either a progressive aerobic program or a stretching-toning control for six months. Forty-three percent were postmenopausal; the aerobic arm produced dose-dependent gains in planning, working memory, and inhibitory control that were largest among the postmenopausal subgroup and absent in the stretching arm. Cardiorespiratory fitness improvements mediated roughly one-third of the cognitive change, consistent with vascular and metabolic pathways.
Two-thirds of Alzheimer’s cases occur in women, and menopause-related estrogen decline accelerates vascular risk and hippocampal atrophy. The observed executive-function benefit aligns with prior observational data linking midlife cardiorespiratory fitness to later-life cognitive trajectories, yet the current study was not powered for Alzheimer’s incidence and excluded women already experiencing mild cognitive impairment.
Confirmation requires a larger, menopause-stratified phase-3 trial that measures both cognitive composites and MRI biomarkers of white-matter integrity and hippocampal volume at 12–24 months. Such a trial would also need to test whether benefits persist after exercise cessation and whether they differ by APOE genotype.
Evidence quality is moderate: the design was randomized but the cognitive analysis was secondary, the sample modest, and follow-up limited to six months; an adequately powered primary-endpoint RCT with biomarker outcomes is the logical next step.
Lancet Neurology: A 300-participant menopause-stratified RCT will report a 0.25–0.35 SD executive-function benefit sustained at 18 months by December 2026.
Sources (2)
- [1]Primary Source(https://content.iospress.com/articles/journal-of-alzheimers-disease/jad230123)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra2201447)